Basilea Pharmaceutica has entered into an agreement with Asahi Kasei Pharma for Basilea’s antifungal drug isavuconazole in Japan. Under the terms of the agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize isavuconazole in Japan. Basilea will receive an upfront payment of approximately $7 million and will be eligible to receive up to approximately $60 million of additional payments upon achievement of regulatory and commercial milestones. Basilea wi...